Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
uniQure Community
NasdaqGS:QURE Community
1
Narratives
written by author
0
Comments
on narratives written by author
11
Fair Values set
on narratives written by author
Community Investing Ideas
uniQure
Popular
Undervalued
Overvalued
uniQure
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
Key Takeaways Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment. Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.
View narrative
US$33.44
FV
60.3% undervalued
intrinsic discount
193.49%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
10 days ago
author updated this narrative
Your Valuation for
QURE
QURE
uniQure
Your Fair Value
US$
Current Price
US$13.28
178.4% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-301m
500m
2015
2018
2021
2024
2025
2027
2030
Revenue US$136.4m
Earnings US$28.2m
Advanced
Set Fair Value